Talk:Tissue-type plasminogen activator

Untitled
In accordance with WikiProject_Drugs naming policy, I propose we move this page to the INN alteplase. If you have any concern with this proposal, please discuss it on this page. Matt 23:15, 21 Dec 2004 (UTC)


 * Since tPA is primarily a human protein, and only secondarily a drug, I don't think that would be a good thing to do. AttishOculus 07:59, 29 December 2006 (UTC)


 * I also think that a recombinant drug shouldn't overtake the physiological protein in significance. We have a precedent in Epogen, that is, recombinant Erythropoietin, which is redirected to the physiological chemical from that search. In most cases this seems reasonable as physiological chemicals administered exogenously have similar effects to their endogenous counterparts (although not the same: e.g. exogenous insulin).  A second page just for the drug would be double handling, but I do also agree that the Drug usage needs to be addressed formally.  Maybe a second Major Heading  further down the page "Alteplase: recombinant Tissue Plasminogen Activator" and a wikiproject drugs format be followed there. I suggest that this will become of increasing importance as more recombiinant drugs appear, and new drugs like alteplase may carry a different moniker than the endogenous protein.  This may even be important enough to bring up in  WikiProject_Drugs and WikiProject Molecular and Cellular Biology if it is not already being hotly debated there.Markjohndaley 15:25, 10 June 2007 (UTC)
 * Alteplase redirects here, and yet the article makes no mention of it, at least I didn't see any... Mauvila (talk) 05:11, 11 June 2008 (UTC)

Lyme disease
Why is this in the "see also" section? cyclosarin (talk) 01:45, 19 June 2012 (UTC)

Stroke
The "ischemic stroke" section is huge, but there is nothing about thrombolysis for MI (still used in areas where there is no primary PCI pathway for STEMI) or pulmonary embolism.

I have rejigged the stroke section as it contained an OR-sounding discussion of the evidence. I have left the content from theNNT in, despite my concerns about it not meeting WP:MEDRS. JFW &#124; T@lk  16:29, 29 June 2015 (UTC)

The information in this section is not an accepted medical opinion. TPA is indicated for stroke less than 4.5 hours old:

Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013; 309:2480. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384:1929. Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA 2015; 313:1451. Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol 2016; 15:925. Lees KR, Emberson J, Blackwell L, et al. Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. Stroke 2016; 47:2373.

Genetic engineering of tPA
Tenecteplase is an example. 10.1111/jth.13033 JFW &#124; T@lk  08:26, 7 September 2015 (UTC)

Functions in brain
Some quite unrelated to actual fibrinolysis 10.1111/jth.13849 JFW &#124; T@lk  11:31, 24 September 2017 (UTC)